EUVIMEDEUVIMED entdecken
Crossref

Targets in the use of biologics for asthma

John Oppenheimer

Journal of Precision Respiratory Medicine · 2019

DOI: 10.2500/jprm.2019.190005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Precision Respiratory Medicine, 2019. Verfasst von John Oppenheimer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a heterogeneous illness. Despite a vast array of treatment options, a significant proportion of patients with asthma continues to lack control of their illness. We now have a new class of asthma therapy in our armamentarium: biologic agents. Presently, the current pricing for all of the biologic agents exceeds measures of cost-effectiveness. Optimal patient selection, through phenotypic indices, is the only likely way to allow these agents to be cost effective. This review examined the literature regarding biologic agents, which stressed attempts at optimizing choice.

Zitieren

APA

Oppenheimer, J. (2019). Targets in the use of biologics for asthma. Journal of Precision Respiratory Medicine. https://doi.org/10.2500/jprm.2019.190005

Vancouver

Oppenheimer J. Targets in the use of biologics for asthma. Journal of Precision Respiratory Medicine. 2019. doi:10.2500/jprm.2019.190005

BibTeX
@article{Oppenheimer2019,
  author = {Oppenheimer, John},
  title = {Targets in the use of biologics for asthma},
  journal = {Journal of Precision Respiratory Medicine},
  year = {2019},
  doi = {10.2500/jprm.2019.190005}
}
Kostenlos starten →